Drugs / BP-C2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04186585 | Apr 2023 → Aug 2025 overdue | prostate cancer | Meddoc | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03627390 | Dec 2014 → Mar 2016 | malignant pancreatic neoplasm | Meabco A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP-C2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04186585 ↗ |
| Modality | Other / unclassified | “BP-C2 is a novel lignin-derived polyphenolic composition with ammonium molybdate.” NCT03627390 ↗ |
| Route | Oral | “15 ml orally once daily for 32 consecutive days” NCT03627390 ↗ |